HK Stock Market Move | CLOUDBREAK-B(02592) fell more than 6% to a new low and announced the withdrawal of the application for clinical trials of the new drug CBT-009.

CLOUDBREAK-B (02592) fell more than 6%, hitting a new low of 1.82 Hong Kong dollars since its listing. As of the time of writing, it dropped 6.09% to 1.85 Hong Kong dollars, with a trading volume of 740,100 Hong Kong dollars. On the news front, on the evening of March 19th, Bokang Vision Cloud announced that the company had held a pre-consultation meeting with the Drug Review Center regarding the application for a new drug clinical trial for CBT-009 eye lotion (a type of atropine eye drops based on perfluoroalkanes, used to treat myopia in teenagers) to be conducted in China and other regions in 2024. Based on the communication at that time, the group officially submitted the application for a new drug clinical trial in December 2025 and was accepted in January 2026. After submitting the application for the new drug clinical trial, the Drug Review Center approved a comparable drug for listing in China. Following further communication with the Drug Review Center, the company believes that conducting the clinical trial in multiple regions, including China, may pose difficulties due to different regulatory requirements in each region. To avoid potential risks in the future development and better allocate the group's resources, the company has decided to voluntarily withdraw the existing application for the new drug clinical trial that may be conducted in China in the third phase.